Patents by Inventor Mark E. Fraley

Mark E. Fraley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
    Patent number: 7262186
    Abstract: The present invention relates to azolopyriniidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: August 28, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, William F. Hoffman
  • Substituted furopyrimidinones as a mitotic kinesin inhibitors
    Patent number: 7244723
    Abstract: The present invention relates to furanopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: July 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman
  • Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors
    Patent number: 7192949
    Abstract: The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: March 20, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Robert M. Garbaccio
  • Tyrosine kinase inhibitors
    Patent number: 7186723
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: March 6, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
  • Tyrosine kinase inhibitors
    Patent number: 7169788
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: January 30, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Mark E. Fraley, George D. Hartman
  • Tyrosine kinase inhibitors
    Patent number: 7125888
    Abstract: The present invention relates to imidazopyridine compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Zhicai Wu
  • Tyrosine kinase inhibitors
    Patent number: 7109204
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: September 19, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, William F. Hoffman, George D. Hartman, Jennifer P. Peckham
  • Tyrosine kinase inhibitors
    Patent number: 7101884
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: September 5, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Mark E. Fraley, Barbara Hanney, Yuntae Kim, Keith L. Spencer
  • Mitotic kinesin inhibitors
    Patent number: 7060705
    Abstract: The present invention relates to quinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: June 13, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, William F. Hoffman
  • Orally active salts with tyrosine kinase activity
    Patent number: 6960590
    Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: November 1, 2005
    Assignee: Merck & Co. Inc.
    Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
  • Mitotic kinesin inhibitors
    Publication number: 20040259826
    Abstract: The present invention relates to quinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: May 7, 2004
    Publication date: December 23, 2004
    Inventors: Mark E. Fraley, William F Hoffmann
  • Tyrosine kinase inhibitors
    Publication number: 20040235875
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 25, 2004
    Inventors: Mark E. Fraley, Kenneth L Arrington, William F Hoffman, George D Hartman, Jennifer P Peckham
  • Tyrosine kinase ihnibitors
    Publication number: 20040235826
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 24, 2004
    Publication date: November 25, 2004
    Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
  • Tyrosine kinase inhibitors
    Publication number: 20040220216
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: March 15, 2004
    Publication date: November 4, 2004
    Inventors: Kenneth L Arrington, Mark E. Fraley, George D. Hartman
  • Tyrosine kinase inhibitors
    Patent number: 6794393
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Publication number: 20040181066
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 29, 2004
    Publication date: September 16, 2004
    Inventors: Mark E. Fraley, William F. Hoffman, George D. Hartman
  • Orally active salts with tyrosine kinase activity
    Publication number: 20040002501
    Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: April 10, 2003
    Publication date: January 1, 2004
    Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
  • Orally active salts with tyrosine kinase activity
    Patent number: 6656942
    Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: December 2, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
  • Tyrosine kinase inhibitors
    Patent number: 6544988
    Abstract: The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Patent number: 6479512
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: November 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Scott R. Hambaugh, Randall W. Hungate